Catalent Stock Rises on Solid Outlook and Deal With Elliot

Catalent stock rises as the company projects a positive revenue outlook for fiscal 2024 and reaches a settlement with activist investor Elliott Investment Management, which will involve an evaluation of the drug manufacturer's business strategy.

barrons.com

Relevant topic timeline:

8/29/2023

Exclusive: Catalent to explore options after Elliott deal-sources

Catalent Inc is reportedly close to reaching a settlement with activist investor Elliott Investment Management, which may involve adding new directors and reviewing strategic alternatives such as a sale of the company.

9/15/2023

CGC, NKLA and BDRX are among pre market gainers (NASDAQ:IOVA)

Iovance Biotherapeutics, Novonix, Nikola Corporation, Yunhong CTI, Canopy Growth, Biodexa Pharmaceuticals, 1847 Holdings, Jiuzi Holdings, and Silvercorp Metals experience stock price increases, with Biodexa Pharmaceuticals seeing the largest gain at 18%.